SGLT2 inhibitor improves CV outcomes in severe heart failure

The benefit was seen regardless of the presence of type 2 diabetes, researchers say

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020

The SGLT2 inhibitor empagliflozin is associated with a reduced risk of hospitalisation and death in patients who have heart failure with reduced ejection fraction (HFrEF), researchers have found.

Findings from the phase 3 EMPEROR-Reduced trial of 3700 patients with HFrEF show lower risk of CV mortality and hospitalisation in those taking 10mg a day of empagliflozin compared with placebo alongside their heart failure drugs

Latest

Trending